PortfoliosLab logoPortfoliosLab logo
IHE vs. NOBL
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

IHE vs. NOBL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares U.S. Pharmaceuticals ETF (IHE) and ProShares S&P 500 Dividend Aristocrats ETF (NOBL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IHE achieves a 6.47% return, which is significantly higher than NOBL's 3.51% return. Over the past 10 years, IHE has underperformed NOBL with an annualized return of 7.81%, while NOBL has yielded a comparatively higher 9.51% annualized return.


IHE

1D
1.16%
1M
1.80%
YTD
6.47%
6M
8.51%
1Y
40.15%
3Y*
17.47%
5Y*
9.98%
10Y*
7.81%

NOBL

1D
-0.17%
1M
1.01%
YTD
3.51%
6M
3.45%
1Y
9.00%
3Y*
8.01%
5Y*
5.03%
10Y*
9.51%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IHE vs. NOBL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
IHE
iShares U.S. Pharmaceuticals ETF
6.47%31.69%8.13%1.06%-4.87%13.07%13.66%15.47%-7.76%10.64%
NOBL
ProShares S&P 500 Dividend Aristocrats ETF
3.51%6.84%6.72%8.09%-6.52%25.46%8.35%27.39%-3.26%21.02%

Correlation

The correlation between IHE and NOBL is 0.49, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.49

Correlation (3Y)
Calculated over the trailing 3-year period

0.56

Correlation (5Y)
Calculated over the trailing 5-year period

0.61

Correlation (10Y)
Calculated over the trailing 10-year period

0.60

Correlation (All Time)
Calculated using the full available price history since Oct 11, 2013

0.61

The correlation between IHE and NOBL shifts across timeframes, from 0.49 (1 year) to 0.61 (5 years), reflecting how their relationship changes across market environments.

IHE vs. NOBL - Sectors Allocation Comparison


Sectors
IHE
NOBL

Healthcare

100.0%
9.7%

Basic Materials

-

10.9%

Communication Services

-

-

Consumer Cyclical

-

5.1%

Consumer Defensive

-

23.5%

Energy

-

3.4%

Financial Services

-

12.4%

Industrials

-

20.3%

Real Estate

-

4.6%

Technology

-

3.6%

Utilities

-

6.4%

Healthcare

IHE
100.0%
NOBL
9.7%

Basic Materials

IHE

-

NOBL
10.9%

Communication Services

IHE

-

NOBL

-

Consumer Cyclical

IHE

-

NOBL
5.1%

Consumer Defensive

IHE

-

NOBL
23.5%

Energy

IHE

-

NOBL
3.4%

Financial Services

IHE

-

NOBL
12.4%

Industrials

IHE

-

NOBL
20.3%

Real Estate

IHE

-

NOBL
4.6%

Technology

IHE

-

NOBL
3.6%

Utilities

IHE

-

NOBL
6.4%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IHE vs. NOBL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IHE
IHE Risk / Return Rank: 7474
Overall Rank
IHE Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
IHE Sortino Ratio Rank: 7575
Sortino Ratio Rank
IHE Omega Ratio Rank: 6565
Omega Ratio Rank
IHE Calmar Ratio Rank: 8585
Calmar Ratio Rank
IHE Martin Ratio Rank: 7575
Martin Ratio Rank

NOBL
NOBL Risk / Return Rank: 2222
Overall Rank
NOBL Sharpe Ratio Rank: 2222
Sharpe Ratio Rank
NOBL Sortino Ratio Rank: 2323
Sortino Ratio Rank
NOBL Omega Ratio Rank: 2020
Omega Ratio Rank
NOBL Calmar Ratio Rank: 2222
Calmar Ratio Rank
NOBL Martin Ratio Rank: 2121
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IHE vs. NOBL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares U.S. Pharmaceuticals ETF (IHE) and ProShares S&P 500 Dividend Aristocrats ETF (NOBL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IHENOBLDifference
Sharpe ratioReturn per unit of total volatility

+1.56

Sortino ratioReturn per unit of downside risk

+2.19

Omega ratioGain probability vs. loss probability

1.40

1.14

+0.26

Calmar ratioReturn relative to maximum drawdown

4.76

0.99

+3.77

Martin ratioReturn relative to average drawdown

14.35

2.58

+11.77

IHE vs. NOBL - Sharpe Ratio Comparison

The current IHE Sharpe Ratio is 2.36, which is higher than the NOBL Sharpe Ratio of 0.80. The chart below compares the historical Sharpe Ratios of IHE and NOBL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


IHENOBLDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.36

0.80

+1.56

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.62

0.35

+0.27

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.43

0.57

-0.14

Sharpe Ratio (All Time)

Calculated using the full available price history

0.51

0.64

-0.14

Drawdowns

IHE vs. NOBL - Drawdown Comparison

The maximum IHE drawdown since its inception was -38.20%, which is greater than NOBL's maximum drawdown of -35.43%. Use the drawdown chart below to compare losses from any high point for IHE and NOBL.


Loading charts...

Drawdown Indicators


IHENOBLDifference

Max Drawdown

Largest peak-to-trough decline

-38.20%

-35.43%

-2.77%

Max Drawdown (1Y)

Largest decline over 1 year

-8.47%

-9.11%

+0.64%

Max Drawdown (3Y)

Largest decline over 3 years

-15.92%

-15.36%

-0.56%

Max Drawdown (5Y)

Largest decline over 5 years

-16.03%

-17.92%

+1.89%

Max Drawdown (10Y)

Largest decline over 10 years

-29.59%

-35.43%

+5.84%

Current Drawdown

Current decline from peak

-2.80%

-5.99%

+3.19%

Average Drawdown

Average peak-to-trough decline

-7.92%

-3.48%

-4.44%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.81%

3.50%

-0.69%

Volatility

IHE vs. NOBL - Volatility Comparison

iShares U.S. Pharmaceuticals ETF (IHE) has a higher volatility of 5.53% compared to ProShares S&P 500 Dividend Aristocrats ETF (NOBL) at 2.36%. This indicates that IHE's price experiences larger fluctuations and is considered to be riskier than NOBL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IHENOBLDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.53%

2.36%

+3.17%

Volatility (6M)

Calculated over the trailing 6-month period

12.48%

8.00%

+4.48%

Volatility (1Y)

Calculated over the trailing 1-year period

17.07%

11.33%

+5.74%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

16.24%

14.38%

+1.86%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

18.05%

16.60%

+1.45%

IHE vs. NOBL - Expense Ratio Comparison

IHE has a 0.42% expense ratio, which is higher than NOBL's 0.35% expense ratio.


Dividends

IHE vs. NOBL - Dividend Comparison

IHE's dividend yield for the trailing twelve months is around 1.65%, less than NOBL's 2.12% yield.


PositionTTM20252024202320222021202020192018201720162015
IHE
iShares U.S. Pharmaceuticals ETF
1.65%1.76%1.73%1.39%2.01%1.49%1.19%1.40%1.25%1.36%0.92%1.93%
NOBL
ProShares S&P 500 Dividend Aristocrats ETF
2.12%2.14%2.05%2.09%1.94%1.89%2.14%1.89%2.37%1.74%2.13%2.02%

Frequently Asked Questions


IHE and NOBL have a correlation of 0.49, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IHE has higher volatility (5.53%) compared to NOBL (2.36%). In terms of maximum drawdown, IHE dropped -38.20% vs NOBL's -35.43%.

On 10-year performance, NOBL leads with 9.51% vs 7.81% for IHE. On fees, NOBL is cheaper at 0.35% per year. On volatility, NOBL has been the lower-risk option at 2.36%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, NOBL has performed better with a 9.51% return vs 7.81%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

NOBL is cheaper with a 0.35% expense ratio, compared with 0.42% for IHE.

NOBL has the higher dividend yield at 2.12%, compared with 1.65% for IHE.

IHE is categorized as Health & Biotech Equities, while NOBL is Dividend. IHE tracks Dow Jones U.S. Select Pharmaceuticals Index, while NOBL tracks S&P 500 Dividend Aristocrats Index. They also come from different issuers: iShares and ProShares. Their fees differ too: 0.42% for IHE and 0.35% for NOBL.

IHE currently has the higher Sharpe Ratio (2.36 vs 0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IHE and NOBL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer